Global cancer biomarkers market is estimated to be valued at USD 28.90 Bn in 2025 and is expected to exhibit a CAGR of 12.9% during the forecast period (2025-2032).
Cancer biomarkers are biological molecules found in blood, tissues or other body fluids that are sign of a normal or abnormal process, or of a condition or disease. These can be used to detect and monitor cancer or cancer progression. In recent years, cancer biomarkers have gained significant attention from both global public and private organizations as these present minimally invasive ways to diagnose, stage and track cancer. Their use also enables oncologists to personalize treatments based on individual patient’s cancer profiles. Advancements in genetic profiling and high-throughput technologies have unlocked the potential of biomarkers that can predict treatment responses and disease progression more accurately. This has promising implications for improving cancer care globally.
Market Dynamics:
Global cancer biomarkers market growth is driven by rising cancer prevalence worldwide, increasing popularity of precision medicine and companion diagnostics, and growing use of biomarkers in drug development as well as approvals. However, high costs associated with biomarker discovery, validation, and commercialization pose a challenge. Moreover, technical limitations and lack of reimbursements restrain the market growth. The market witnesses lucrative opportunities from emerging economies with large cancer populations and growing health expenditures. Further opportunities lie in discovery of novel biomarkers especially for hard-to-treat cancers through ongoing research efforts.
Key Features of the Study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook